Erythema multiforme major induced by sunitinib for metastatic renal cell carcinoma

Publication date: Available online 4 June 2019Source: Urology Case ReportsAuthor(s): Daisuke Watanabe, Akemi Yamashita, Tadaaki Minowa, Kunihisa Miura, Akio MizushimaAbstractThere are currently several options for tyrosine kinase inhibitor as a systemic therapy for metastatic renal cell carcinoma (mRCC). The successful control of adverse events caused by such drugs, along with eliciting long-term maximum effect, are the major issues with respect to the treatment strategy for mRCC. We herein report the clinical course of mRCC, in which erythema multiforme major was observed on the 13th day of the first course of sunitinib, but the symptoms improved after the immediate withdrawal of sunitinib, as well as the administration of topical steroids and oral antihistamines alone.
Source: Urology Case Reports - Category: Urology & Nephrology Source Type: research